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Abstract 39 
Background. Accurate assessment of the serotype distribution associated with 40 
pneumococcal colonization and disease is essential for the evaluation and 41 
formulation of pneumococcal vaccines and informing vaccine policy. 42 
 43 
Methods. We evaluated pneumococcal serotyping concordance between latex 44 
agglutination, PneumoCaT by whole genome sequencing (WGS) and DNA 45 
microarray using samples from community carriage surveillance in Blantyre, Malawi. 46 
Nasopharyngeal swabs were collected, following WHO recommendations, between 47 
2015 and 2017, using stratified random sampling among study populations. 48 
Participants included healthy children 3–6 years old (PCV13 vaccinated as part of 49 
EPI), healthy children 5–10 years (age-ineligible for PCV13), and HIV-infected adults 50 
(18–40yrs) on ART. For phenotypic serotyping we used a 13-valent latex kit (SSI, 51 
Denmark). For genomic serotyping we applied PneumoCaT pipeline to whole 52 
genome sequence libraries. For molecular serotyping by microarray we used the 53 
BUGS Bioscience Senti-SP microarray. 54 
 55 
Results. 1347 samples were analysed. Concordance was 90.7% (95% CI: 89.0–56 
92.2) between latex and PneumoCaT; 95.2% (93.9–96.3) between latex and 57 
microarray; and 96.6% (95.5–97.5) between microarray and PneumoCaT. By 58 
detecting additional vaccine serotype (VT) pneumococcus carried at low relative 59 
abundance (median 8%), microarray increased VT detection by 31.5% compared to 60 
latex serotyping. 61 
 62 
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Conclusion. All three serotyping methods were highly concordant in identifying 63 
dominant serotypes. Latex serotyping is accurate in identifying vaccine-serotypes 64 
and requires the least expertise and resources for field-implementation and analysis. 65 
However, WGS, which adds population structure, and microarray, which adds 66 
multiple-serotype carriage, should be considered at regional reference laboratories 67 
while investigating the importance of VT in low relative abundance in transmission 68 
and disease. 69 
 70 
Introduction 71 
Streptococcus pneumoniae colonises the nasopharynx of healthy individuals. 72 
Although carriage is usually asymptomatic, nasopharyngeal (NP) colonization is a 73 
prerequisite for disease including otitis media, sinusitis, pneumonia, bacteraemia, 74 
and meningitis. (1) The pneumococcus is estimated to be responsible for over 318 75 
000 (uncertainty ratio [UR]: 207 000–395 000) deaths every year in children aged 1 76 
to 59 months, with the highest mortality burden among African children.(2) Evidence 77 
also shows that HIV-infected children and adults are at significantly higher risk of 78 
invasive pneumococcal disease (IPD) than their HIV-uninfected counterparts. (3, 4)  79 
 80 
Current multivalent pneumococcal conjugate vaccines (PCV) target subsets of the 81 
100 capsular serotypes known to be expressed by the pneumococcus. PCV reduces 82 
nasopharyngeal carriage of the sub-set of pneumococcal serotypes they contain, 83 
known as vaccine serotypes (VT). With reduced carriage among the vaccinated 84 
there is then reduced risk of VT-IPD (direct protection) and reduced transmission, 85 
therefore reduced risk of VT-IPD among those PCV-unvaccinated (indirect 86 
protection). However, non-vaccine serotypes (NVT) have the potential to fill the 87 
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ecological niche, becoming more common in carriage and disease. (5-7) This 88 
phenomenon, known as serotype replacement, may be more pronounced in low-89 
income settings because of higher prevalence, density and diversity of 90 
pneumococcal carriage, and represents a considerable risk to the global 91 
pneumococcal immunisation strategy.(8) Serotype distribution differs between 92 
continents as well as individual countries. (9) Given these differences, accurate 93 
assessment of the serotype distribution associated with both pneumococcal 94 
colonization and pneumococcal disease is needed in the evaluation, formulation and 95 
delivery of pneumococcal vaccines. 96 
 97 
A pneumococcal serotyping method suitable for use in robust carriage and 98 
surveillance studies should therefore, at minimum, be accurate in its serotype 99 
assignment, particularly in relation to VTs. Additional desirable parameters include 100 
detection of most or all serotypes, ability to detect multiple serotypes in carriage 101 
(common in high burden settings (10, 11), more in-depth information on genotype, 102 
suitable to scale up for large projects, and practical for resource-poor settings. 103 
Unfortunately, work in resource-poor settings can too often limit the number of these 104 
parameters that can be achieved. 105 
 106 
The gold-standard serotyping method, the Quellung reaction, was developed in the 107 
early 1900s and is performed by testing colonies with a set of type-specific antisera. 108 
(12) Bacteria are observed by microscopy, with serotype defined by observing 109 
apparent capsular swelling in reaction to the type-specific antisera. It is laborious, 110 
requires frequent use to maintain skills, requires a complete set of type-specific 111 
antisera, and is therefore mainly performed by reference laboratories. The 112 
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PneuCarriage project, a large, multi-centre study, was established with the aim of 113 
identifying the best pneumococcal serotyping methods for carriage studies. (13) The 114 
Project identified microarray with a culture amplification step as the top-performing 115 
method. While robust and systematic, their decision algorithm did not take into 116 
account parameters such as cost, skill level and resources needed for assay 117 
implementation and maintenance, as well as output processing and interpretation.  118 
 119 
Here we describe, in the context of an ongoing field-based study, (14) the level of 120 
concordance between three methods commonly used during ongoing routine 121 
pneumococcal surveillance activities in our work: latex agglutination, microarray and 122 
serotyping-by-sequencing. We also address parameters that researchers and 123 
policymakers can consider when deciding which assay to implement in their local 124 
setting. 125 
 126 
Materials and Methods 127 
Study Setting 128 
Blantyre is located in southern Malawi with an urban population of approximately 1.3 129 
million.  130 
 131 
Study Population and Recruitment 132 
Samples were collected as part of a larger 3.5-year pneumococcal carriage 133 
surveillance project, as described elsewhere. (14) In brief, this was a prospective 134 
rolling cross-sectional observational study using stratified random sampling to 135 
measure pneumococcal nasopharyngeal carriage in Blantyre, Malawi. Samples used 136 
in this analysis were collected during the first two years of twice-annual cross-137 
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sectional surveys, from June 2015 to April 2017. Recruitment included three groups: 138 
i) healthy children 3–6 years old who received PCV13 as part of routine EPI, ii) 139 
healthy children 5–10 years old who were age-ineligible to receive PCV13 as part of 140 
EPI, and iii) HIV-infected adults (18–40yrs) on ART. 141 
 142 
Sample Selection 143 
For concordance analyses between the three methods, all samples were included 144 
that had serotyping results available from each of the three methods (latex, 145 
microarray, serotyping-by-sequencing). From the total nasopharyngeal swab (NPS) 146 
samples collected during the larger surveillance project (including 1,044 from 147 
children 3–6 years old [PCV-vaccinated], 531 children 5–10 years old [PCV-148 
unvaccinated, age-ineligible] and 428 HIV-infected adults on ART), 1347 samples 149 
were culture-confirmed for S. pneumoniae and also had results available from the 150 
microarray and serotyping-by-sequencing. The final concordance analysis included 151 
846 children 3–6 years old (PCV13-vaccinated), 422 children 5–10 years old (age-152 
ineligible for PCV13 vaccination) and 79 adults (HIV-infected and PCV13-153 
unvaccinated). (Figure 1) Sample selection for microarray and serotyping-by-154 
sequencing was done independently and blind to latex serotype data. 155 
 156 
Nasopharyngeal Swab Collection 157 
Collection of NP swabs is described elsewhere. (14) In brief, an NP swab sample 158 
was collected from each participant using a nylon flocked swab (FLOQSwabsTM, 159 
Copan Diagnostics, Murrieta, CA, USA) and then immediately placed into 1.5mL 160 
skim milk-tryptone-glucose-glycerol (STGG) medium and processed at the Malawi–161 
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Liverpool–Wellcome Trust (MLW) laboratory in Blantyre, according to WHO 162 
recommendations. (15) Samples were frozen on the same day at −80°C. (Figure 2) 163 
 164 
NPS Culture for Pneumococcal Screening & Serotyping 165 
30uL NPS–STGG was plated on a sterile sheep blood-gentamicin (SBG; 7% SBA, 5 166 
µl gentamicin/mL) agar plate (primary plate) and incubated overnight at 37°C in ~5% 167 
CO2. Plates showing no S. pneumoniae growth were incubated overnight a second 168 
time before being reported as negative. S. pneumoniae was identified by colony 169 
morphology and optochin disc (Oxoid, Basingstoke, UK) susceptibility. The bile 170 
solubility test was used on isolates with no or intermediate (zone diameter <14mm) 171 
optochin susceptibility. A single colony of confirmed pneumococcus was selected 172 
and grown on a sterile SBG plate (secondary plate), following the same process as 173 
the primary plate. (Figure 1) 174 
 175 
Latex Serotyping 176 
Pneumococcal growth from secondary plates was used for serotyping by latex 177 
agglutination (ImmuLex™ 7-10-13-valent Pneumotest; Statens Serum Institute, 178 
Denmark), following manufacturer guidelines. Using a reaction card and a sterile 179 
inoculation loop, a small sweep of an overnight bacterial culture was mixed with 180 
saline and a series of individual Pneumotest-Latex reagents in suspension. The card 181 
was rocked manually and observed for agglutination. A Pneumotest-Latex 182 
chessboard was used to determine which serotype is associated with the observed 183 
set of agglutination reactions. The kit allows for differential identification of each 184 
PCV13 VT (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F). Other than for a 185 
limited number of serogroups (6, 7, 9, 18, 19, 23) for which the kit provides 186 
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serogroup differentiation, there is no further differential identification of NVT 187 
serogroups or serotypes. NVT and non-typeable isolates were reported as NVT. 188 
Samples were batch-tested on a weekly basis, with technicians blinded to the 189 
sample source. After serotyping was complete, the remaining growth from each 190 
secondary plate was archived at -80°C in sterile STGG. Refer to Text S1 in the 191 
supplemental material for a more detailed description of latex serotyping. 192 
 193 
Molecular Serotyping by Microarray 194 
For samples with culture-confirmed pneumococcal carriage, the original inoculated 195 
STGG was thawed and vortexed. Aliquots of 100µl were shipped in 1.8mL cryovials 196 
to BUGS Bioscience (BUGS Bioscience Ltd., London, United Kingdom) on dry ice. 197 
(Figure 1) The remaining steps for microarray serotyping (including sample 198 
processing, culturing, DNA extraction, microarray and analysis) were completed 199 
entirely by BUGS Bioscience. (16, 17) Final microarray results were retrieved by the 200 
study team from BUGS Bioscience web-based SentiNET platform and imported into 201 
STATA 13.1 (StataCorp, College Station, TX, USA) for analysis. Refer to Text S1 in 202 
the supplemental material for a more detailed description of microarray serotyping. 203 
 204 
DNA Extraction and WGS 205 
Archived secondary growth isolates were used to develop sequence libraries for 206 
serotyping-by-sequencing. To optimise total retrieved DNA, 30µl of thawed isolate-207 
STGG was incubated overnight in 6mL THY (Todd Hewitt broth + yeast) enrichment 208 
culture. DNA was extracted from the overnight culture using the Qiagen® QIAampTM 209 
DNA Mini Kit, following manufacturer guidelines for bacterial DNA. Quality control 210 
(QC) measures, as required by the guidelines of the sequencing institution, included 211 
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DNA quantification (QubitTM, Thermo Fisher Scientific, Massachusetts, USA) of all 212 
DNA samples and gel electrophoresis imaging on 0.7% agarose to assess DNA 213 
integrity. After attaining quantity and quality requirements, 100μL of extracted DNA 214 
were aliquoted into skirted 96-well microwell plates and stored at -80⁰C until shipped 215 
on dry ice to the Oxford Genomics Centre (University of Oxford, United Kingdom) for 216 
sequencing. Whole genome sequencing was performed at the Oxford Genomics 217 
Centre on a HiSeq4000 platform (Illumina™), with paired-end libraries and a read 218 
length of 150bp. 219 
 220 
Serotyping-by-sequencing 221 
WGS data was retrieved by the study team from a web-based FTP link. Serotype 222 
was inferred from the isolates’ genome sequences using the PneumoCaT software 223 
pipeline, an opensource bioinformatic tool. (18) PneumoCaT requires raw 224 
sequencing reads for each isolate which were trimmed and cleaned. Reads were 225 
trimmed of the illumina adapters and cleaned of low-quality ends using Trimmomatic 226 
(ver. 0.38; available at http://www.usadellab.org/cms/?page=trimmomatic). Minimum 227 
read length after trimming was 80 base pairs (bp), with the minimum average quality 228 
for a sliding window of 4 nucleotide being 15. A subset of 700,000 reads per end (1.4 229 
million total) was used for any subsequent analysis. XML result files were parsed 230 
with ad-hoc bash scripts, in order to extract and tabulate the serotyping result for 231 
each isolate. PneumoCaT was installed and used on a Linux machine at the MRC 232 
Cloud Infrastructure for Microbial Bioinformatics (CLIMB; https://www.climb.ac.uk/). 233 
Each serotype identification required an average 5-8 minutes. Refer to Text S1 in the 234 
supplemental material for a more detailed description of serotyping-by-sequencing. 235 
 236 
 on N
ovem
ber 2, 2020 at S
T
 G
E
O
R
G
E
'S
 LIB
R
A
R
Y
http://jcm
.asm
.org/
D
ow
nloaded from
 
11 
 
Definitions 237 
Concordance was calculated with all samples aggregated and according to the level 238 
of discrimination provided by the method. Concordance is reported using two criteria: 239 
i) a criterion based on whether both assays reported NVT or both reported VT 240 
(VT/NVT criterion) and ii) a criterion based on whether the final serotype reported by 241 
each assay is equivalent (serotype-specific criterion). 242 
 243 
Concordance between latex and serotyping-by-sequencing (PneumoCaT): Other 244 
than a limited number of serogroups (6, 7, 9, 18, 19, 23) for which the latex kit 245 
provides serogroup differentiation, there is no further differential identification of NVT 246 
serogroups to serotype. NVT and non-typeable isolates were reported as NVT. 247 
Concordance at serotype level (serotype-specific criterion) was reported only if latex 248 
reported VT carriage. If latex reported NVT, any NVT reported by PneumoCaT was 249 
considered concordant. For example: 23F reported by both latex and PneumoCaT 250 
was considered concordant, as was NVT and 15B. However, 19F and 19A was 251 
considered discordant, as was NVT and 6B. 252 
 253 
Concordance between latex and microarray: Concordance at serotype level 254 
(serotype-specific criterion) was reported only if latex reported VT carriage. If latex 255 
reported NVT, any NVT reported by microarray was considered concordant. 256 
Because microarray reports multiple serotype carriage, 23F reported by latex and 257 
23F+34 reported by microarray was considered concordant, as was NVT and 258 
18C+33D. However, 19F and 33D+19A was considered discordant, as was NVT and 259 
3+7F. 260 
 261 
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Note that for microarray, some closely related serotypes are reported as a group, 262 
with the final individual serotype call in brackets (e.g., 6A/B [6B]). In this case, results 263 
were analysed using the individual serotype call. For example, if microarray reported 264 
6A/B [6B], this was considered discordant to a 6A latex result and concordant to a 265 
6B latex result. For simplicity of analysis, if a method did not claim to detect a 266 
serotype but the sample contained that serotype, this result was deemed discordant. 267 
For example, if microarray detected both serotypes 23F and 19A but latex detected 268 
only serotype 3, this result was considered discordant. 269 
 270 
Concordance between microarray and serotyping-by-sequencing (PneumoCat): 271 
Microarray and PneumoCat both differentiate VT and NVT to serotype level, allowing 272 
concordance to be calculated on serotype concordance (serotype-specific criterion) 273 
for both VT and NVT S. pneumoniae. 274 
 275 
Statistical analysis 276 
The formula for percent increase in VT prevalence was: ([VT prevalence using latex 277 
– VT prevalence using microarray] / VT prevalence using latex) * 100%. Confidence 278 
intervals are binomial exact. Statistical significance was inferred from two-sided 279 
p<0.05. Participant data collection was completed using Open Data Kit (ODK) 280 
Collect open source software. (v1.24.0). Statistical analyses were completed using 281 
Stata 13.1 (StataCorp, College Station, TX, USA). 282 
 283 
Ethics Considerations 284 
The study protocol was approved by the College of Medicine Research and Ethics 285 
Committee, University of Malawi (P.02/15/1677) and the Liverpool School of Tropical 286 
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Medicine Research Ethics Committee (14.056). Adult participants and 287 
parents/guardians of child participants provided written informed consent; children 8-288 
years and older provided informed assent. This included consent for publication. 289 
 290 
Results 291 
Pneumococcal carriage prevalence results from the larger surveillance project are 292 
reported elsewhere. (14) Comparing latex and PneumoCat, the adjusted 293 
concordance of correctly identifying pneumococcal carriage as VT or NVT was 294 
90.7% (1216/1341; 95% CI: 89.0–92.2). (Figure 3) Based on the serotype-specific 295 
criterion, concordance between latex and PneumoCaT was 87.5%; (1174/1341) 296 
(95% CI: 85.7–89.3). Comparing latex and microarray, the concordance based on 297 
correctly identifying pneumococcal carriage as VT or NVT was 97.3% 1311/1347 298 
(95% CI: 96.3–98.1). Based on a serotype-specific criterion, the concordance was 299 
95.2% (1282/1347; 95% CI: 93.9–96.3). Comparing microarray and PneumoCaT, 300 
concordance based on correctly identifying pneumococcal carriage as VT or NVT 301 
was 96.6% (1295/1341; 95% CI: 95.5–97.5). Based on a serotype-specific criterion, 302 
the concordance was 82.8% (1110/1341; 95% CI: 80.6–84.8). 303 
 304 
Increased VT Detection Using Microarray 305 
Using a larger study database of 1,949 samples from the same study, we evaluated 306 
latex and microarray data. Aggregating all ages (i.e. child and adult), there was an 307 
increase of 31.5% in VT prevalence by microarray compared to latex serotyping: 308 
43.0% increase in VT carriage among children 3–6 years old, 21.7% among children 309 
5–10 years old and 10.8% among HIV-infected adults on ART (Table 1). This was 310 
due to samples reporting NVT by latex but that also carried VT, as detected by 311 
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microarray. These VT, undetected by latex, were carried in lower relative abundance 312 
(median 8%, range: 2% - 48%). The prevalence of multiple serotype carriage (range 313 
2-6 serotypes) was 35.2% (686/1949). The prevalence among respective age groups 314 
was 44.4% (457/1029), 32.8% (169/515), and 14.8% (60/405). Among samples with 315 
multiple serotype carriage, latex identified the dominant serotype in 85.3% (585/686; 316 
95%CI: 82.4–87.8) of samples. Despite the overall increase in detection of VT 317 
carriage, the proportion of individual VT serotypes detected is not different when 318 
comparing microarray to latex (Figure 4). Refer to Table S1 in the supplemental 319 
material for the reported frequency of each vaccine serotype (VT) detected by 320 
microarray and latex. 321 
 322 
Key Parameters of selected serotyping methods.  323 
Table 2 presents key parameters to further consider when deciding which assay is 324 
appropriate for a particular setting. Estimated costs and feasibility of implementation 325 
and maintenance are specific to the setting in Malawi at the Malawi-Liverpool-326 
Wellcome Trust Clinical Research Programme in Blantyre. Extrapolation would need 327 
further validation outside the scope of this evaluation. Though more limited in its 328 
reporting only a single serotype, latex is highly accurate while being less costly and 329 
requiring less expertise and resources for field-implementation and analysis. While 330 
microarray is the costliest option, it provides greater accuracy of total pneumococcal 331 
carriage, including multiple serotype carriage and relative abundance of individual 332 
serotypes in carriage. Whole genome sequencing is a strong alternative to latex and 333 
would be nearly cost-free if the sequence libraries were already available. In 334 
addition, WGS provides opportunity for further analyses, including population 335 
structure and antibiotic resistance. 336 
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 337 
Discussion 338 
We report high concordance between three serotyping techniques applicable to 339 
routine pneumococcal surveillance. Importantly, we have extended the analysis to 340 
include relevant parameters beyond accuracy including cost, time to result, and 341 
measures of input required for assay implementation and maintenance. These are 342 
parameters that researchers and policy makers should consider when deciding 343 
which assay to implement. All three assays appear accurate and concordant in 344 
identifying the dominant serotype.  345 
 346 
While latex agglutination is accurate and requires the least expertise and resources 347 
for field-implementation and analysis and provides rapid results, standard latex 348 
approaches is not optimal for optimal surveillance of vaccine impact, including the 349 
detection of multiple serotype carriage and VT in low relative abundance. (19) There 350 
have been attempts to implement latex for detection of multiple serotype carriage. 351 
Gratten et al. serotyped up to six colonies from nasal-swab culture plates and found 352 
multiple-serotype carriage in 29.5% of Papua New Guinean children. (20) The 353 
authors went on to serotype at least 50 colonies from 10 selected nasal-swab 354 
cultures and concluded that the minor carried serotype accounted for 4 to 27% of the 355 
total pneumococcal population. A review of published data on multiple carriage 356 
concluded that, to detect a minor carried serotype it would be necessary to serotype 357 
at least five colonies to have a 95% chance of detecting the serotype if it accounted 358 
for 50% of the total pneumococcal population, and one would need to examine 299 359 
colonies if the serotype was present at a relative abundance of 1%. As part of the 360 
PneuCarriage project, to thoroughly characterise samples, up to 120 colonies from 361 
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each sample were selected to achieve >99% power to detect a minor serotype of 5% 362 
abundance. (13) This approach would not be cost- or time-effective. Though 363 
dependent on technical capacity to develop in-house reagents, researchers in The 364 
Gambia developed a latex agglutination technique in which colonies from the primary 365 
culture plate are suspended in saline and serotyped by latex agglutination. (21)  366 
While not differentiating NVT serotypes, they did show that up to 10.4% of 367 
pneumococcal acquisitions were found to be of multiple serotypes in a longitudinal 368 
infant cohort study. While latex is limited in its output, the process can be leveraged 369 
for additional endpoints including, for example, measuring carriage density through 370 
counting of colony-forming units (CFU) on agar culture plates. What’s more, though 371 
less cost- and time-effective, use of both commercial products (including Statens 372 
Serum Institute, Denmark) and production of in-house latex serotyping reagents has 373 
been well-documented to significantly expand the number of NVT serotypes that can 374 
be differentiated by latex, including quality control procedures. (11, 22) 375 
 376 
With opensource bioinformatic tools such as PneumoCaT, serotyping-by-sequencing 377 
can be less costly than microarray, even accounting for costs of DNA extraction and 378 
WGS, while still being able to differentiate non-typeable and nearly every known VT 379 
and NVT. Though we would not recommend initiating DNA extraction and WGS for 380 
the use of PneumoCaT alone, sequence libraries can be further leveraged for 381 
extensive informative bioinformatic analyses, useful in population biology, 382 
antimicrobial resistance investigations and vaccine monitoring. Moreover, using 383 
PneumoCaT for serotyping would be essentially cost-free if the sequence libraries 384 
were already available, apart from the limited bioinformatic skills needed. While 385 
microarray is more costly, it differentiates NVT and multiple serotype carriage with 386 
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relative abundance, as well as non-S. pneumoniae contaminants (i.e. S. mitis, S. 387 
salivarius, Staphylococcus aureus) with a degree of precision. This technique stands 388 
out for its sensitivity, being able to detect serotypes in low relative abundance, which 389 
is of critical importance for understanding the transmission patterns of S. 390 
pneumoniae.  Having the extra counts for each serotype from the same number of 391 
samples, as provided by microarray, also has the advantage of adding power to a 392 
study’s statistics. 393 
 394 
There are a number of limitations to mention, including the number of serotyping 395 
methods which were not evaluated, including PCR and the SeroBA pipeline. SeroBA 396 
is a relatively new serotyping-by-sequencing software. With similar accuracy to 397 
PneumoCaT, SeroBA does have operational advantages. (23) SeroBA can correctly 398 
call a serotype with a read coverage as low as 10X (20X is required for 399 
PneumoCaT). Using a k-mer based approach, rather than the raw sequence 400 
alignment, SeroBA requires much lower computational power and time. On the other 401 
hand, the PneumoCaT source code can be easily adapted to the operator needs, 402 
and both software are likely to run on a standard server configuration. Alternative 403 
culture-independent methods, such as isolation-independent conventional multiplex 404 
PCR-serotyping (cmPCR) could be important for confirming carriage when re-405 
culturing of original NP swab samples is not feasible. Though cmPCR has been 406 
successfully applied on DNA extracted directly from NPS-STGG, evidence suggests 407 
that cmPCR serotyping after culture enrichment returns a higher sensitivity and an 408 
ability to identify multiple serotype carriage. (9) Nonetheless, cmPCR can be 409 
confounded by non-pneumococcal streptococci (including S. mitis, S. oralis and S. 410 
parasanguinis). (24) Due to a high sequence similarity with target serotype-specific 411 
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amplicons, cmPCR can overestimate pneumococcal carriage. Carvalho et al., for 412 
example, reported that 82.5% of samples (combined nasopharyngeal and 413 
oropharyngeal swabs) that were positive for pneumococcus by cmPCR were culture-414 
negative by latex. Similarly, 35.0% of those positive for pneumococcus by cmPCR 415 
were negative by lytA-pnemococcal specific PCR. This is particularly problematic 416 
when bacterial DNA is extracted from culture-enriched naso- and oropharyngeal 417 
samples, requiring PCR results to be confirmed by latex agglutination or other 418 
serotyping procedures. (24) Additional PCR limitations include the need for region-419 
specific reaction protocols, implementing a high number of primer pairs to identify the 420 
same range of serotypes identified by microarray or WGS, and the increased risk of 421 
detecting non-viable pneumococci. As there is no evidence of a viable but non-422 
culturable (VBNC) state in S. pneumoniae, (25) identifying non-viable pneumococci 423 
could be disadvantageous for field-based research. While a formal economic 424 
analysis of the methods would be justified, we were unable to extrapolate the 425 
individual costing components between sites. Such components would include local 426 
salaries and additional labour costs, procurement and shipping of equipment and 427 
consumables, equipment maintenance, local health and safety requirements, and 428 
institutional costs. For this reason, comparative costing is grossly categorized. 429 
Though we did not include invasive isolates (from blood or cerebrospinal fluid, for 430 
example), it is important to identify serotypes associated with IPD, including in post-431 
PCV impact studies. For invasive isolates, with a single-serotype sample expected, 432 
microarray would have limited advantage. Application of serotyping-by-sequencing 433 
would then be the most informative option, including insight into population structure, 434 
antimicrobial resistance patterns and serotype replacement disease. 435 
 436 
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CONCLUSION 437 
Selection of the appropriate assay should be based on the intended analysis and 438 
endpoint. While accuracy and concordance is high between the three assays, 439 
parameters of field-implementation and cost vary significantly. In a setting of limited 440 
resources, as is true throughout much of sub-Saharan Africa, latex is the best overall 441 
option for decentralised surveillance of vaccine impact. However, WGS, which adds 442 
population structure, and microarray, which adds multiple-serotype carriage, should 443 
be considered at regional reference laboratories while investigating the importance 444 
of VT in low relative abundance in transmission and disease. 445 
 446 
Supplemental Material 447 
Supplemental material is available online. Consisting of data provided by the authors 448 
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corresponding author. 451 
 452 
Data availability. The data supporting the findings of this study has been deposited 453 
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Figure legends 563 
Figure 1 Sample selection for analysis. Sample were collected during 4 rolling cross-564 
sectional surveys from June 2015 to April 2017. From the total nasopharyngeal swab 565 
samples collected 1347 samples had results available from the three assays under 566 
review. The method of selection for microarray and PneumoCaT was done 567 
independent of available latex serotype data. 568 
 569 
Figure 2 Laboratory procedures. Nasopharyngeal swabs (NPS) were inoculated into 570 
STGG and subsequently plated on a growth agar of sheep blood and gentamycin. 571 
Bacteria growth (from single-colony picks) from samples culture-confirmed for 572 
Streptococcus pneumoniae were used for latex serotyping. Remaining pure-growth 573 
isolates, retained at -80°C in sterile STGG, were later grown for DNA extraction and 574 
WGS. Aliquots of original samples (NPS-STGG) that were culture-confirmed for 575 
Streptococcus pneumoniae were assessed by microarray. NPS=nasopharyngeal 576 
swabs, STGG=skim-milk-tryptone-glucose-glycerol, WGS=whole-genome 577 
sequencing, Spn=Streptococcus pneumoniae, SBG=sheep blood and gentamycin, 578 
SSI= Statens Serum Institute, 13v=13-valent, NSP-STGG=NPS inoculated into 579 
STGG. 580 
 581 
Figure 3 Concordance between assays. Concordance between two assays was 582 
defined as both assays identifying pneumococcal carriage as VT or both as NVT. 583 
Latex and PneumoCaT reported one result per sample, both using the same pure-584 
growth culture. Microarray, using an aliquot of the original NPS-STGG, differentiated 585 
individual serotypes in multiple serotype carriage, when present. When comparing 586 
the three assays, concordance was based on serotype if latex reported VT carriage. 587 
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If latex reported NVT, this was considered concordant to any NVT reported by 588 
PneumoCaT and microarray, as long as PneumoCaT and microarray reported the 589 
same NVT. 590 
 591 
Figure 4 Proportion of individual VT serotypes contributing to total VT carriage. The 592 
proportion of individual VT serotypes detected is not significantly different when 593 
comparing microarray to latex. Refer to Table S1 in the supplemental material for the 594 
reported frequency of each vaccine serotype (VT) detected by microarray and latex. 595 
VT=vaccine serotype. 596 
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 627 
Table 1 Increased detection of VT carriage, latex vs microarray 628 
 Latex 
VT prevalence (n) 
95% CI 
Microarray 
VT prevalence (n) 
95% CI 
% Increase 
in VT prevalence 
Children 3-6 years, 
PCV-vaccinated (n=1360) 
20.0% (272) 
17.9, 22.2 
28.6% (389) 
26.2, 31.1 
43.0% 
Children 5-10 years, 
PCV-unvaccinated (n=904) 
21.1% (191) 
18.5, 23.9 
26.5% (240) 
23.7, 29.6 
21.7% 
Adults, 18-40 years, HIV-infected,  
PCV-unvaccinated (n=963) 
14.2% (137) 
12.1, 16.6 
16.6% (160) 
14.3, 19.1 
10.8% 
Total (n=3227) 
18.6 (600) 
17.3, 20.0 
24.4 (789) 
23.0, 26.0 
31.5% 
PCV=pneumococcal conjugate vaccine, VT=vaccine serotype, CI=confidence 629 
interval.  630 
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Table 2 Key comparative parameters of serotyping methods. 631 
 632 
1Estimated costs and feasibility of implementation and maintenance are specific to the study requirements and laboratory capacity 633 
(including no capacity for WGS or microarray) at the Malawi-Liverpool-Wellcome Trust Clinical Research Programme in Blantyre.  634 
2 AMR profile cannot be assigned to a single strain in a sample with multiple-serotype or multiple-pathogen carriage.  635 
 Latex (phenotypic) Microarray (genomic) PneumoCaT (genomic) 
Assay implementation 
Sample used in assay  Pure growth from single isolate  Original sample in STGG  Pure growth from single isolate 
Cost estimate
1
  Lowest of three assays  Highest of three assays  Middle of three assays 
Implementation of assay
1
  Least difficult (relatively simple)  Most difficult  Moderate difficult 
Training required for 
implementation 
 Minimal  Advanced  DNA extraction: moderate 
 WGS library manipulation: advanced 
 PneumoCaT tool: moderate 
Training required for 
processing and interpretation 
of results 
 Minimal  Moderate  Moderate 
    
Assay output and interpretation 
Serotypes reported  Single  Multiple, if present  Single 
NVT differentiation  No
3
  Yes  Yes 
Relative abundance of 
individual serotypes reported 
 No  Yes  No 
Additional outputs  Isolates archived and available for 
further analyses 
 AMR profile
2
 
 NT differentiation 
 WGS library accessible for further 
analyses, including population structure 
and AMR 
Conclusion  Adequate for surveillance 
 Limited resolution for optimal VE 
estimation 
 Cost and technique limits ability to 
de-centralise implementation 
 Detection of VT in low relative 
abundance is of critical 
importance 
 Sentinel sites should be 
considered for regional NVT & VT 
resolution for optimal VE 
estimation 
 Limited resolution for optimal VE 
estimation 
 No benefit over latex unless WGS library 
already available 
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3NVT & NT reported as NVT.  Use of both commercial products and production of in-house latex serotyping reagents can 636 
significantly increase the number of NVT serotypes that can be differentiated by latex.637 
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